Thioredoxin-interacting protein suppresses bladder carcinogenesis

Carcinogenesis

Volumn 32, Issue 10, 2011, Pages 1459-1466

  Nishizawa, Koji ^a   Nishiyama, Hiroyuki ^a   Matsui, Yoshiyuki ^a   Kobayashi, Takashi ^a,b   Saito, Ryoichi ^a   Kotani, Hirokazu ^c   Masutani, Hiroshi ^d   Oishi, Shinya ^e   Toda, Yoshinobu ^a   Fujii, Nobutaka ^e   Yodoi, Junji ^d   Ogawa, Osamu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Columbia University College of Physicians and Surgeons ^*  (United States)

^c KYOTO UNIVERSITY   (Japan)

^d KYOTO UNIVERSITY   (Japan)

^e Graduate School of Pharmaceutical Sciences   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1; TF 14016; THIOREDOXIN INTERACTING PROTEIN; UNCLASSIFIED DRUG;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER CELL; CANCER MODEL; CHEMICAL CARCINOGENESIS; CLINICAL ARTICLE; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; WILD TYPE;

AGED; ANIMALS; BLOTTING, WESTERN; BUTYLHYDROXYBUTYLNITROSAMINE; CARRIER PROTEINS; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, CXCR4; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; SURVIVAL RATE; THIOREDOXINS; URINARY BLADDER NEOPLASMS;

EID: 80053165531     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgr137     Document Type: Article

References (30)

1. Jemal,A. et al. (2010) Cancer statistics, 2010. CA Cancer J. Clin., 60, 277-300.
2. Cookson,M.S. et al. (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J. Urol., 158, 62-67.
3. Hashimoto,Y. et al. (1974) In vitro neoplastic transformation of epithelial cells of rat urinary bladder by nitrosamines. Nature, 252, 497-499.
4. Weinberg,R.A. (2007) The Biology of Cancer. Garland Science, New York, NY chapters 5-7.
5. McCubrey,J.A. et al. (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta, 1773, 1263-1284.
6. Yao,R. et al. (2004) Altered gene expression profile in mouse bladder cancers induced by hydroxybutyl(butyl)nitrosamine. Neoplasia, 6, 569-577.
7. Retz,M.M. et al. (2005) CXCR4 expression reflects tumor progression and regulates motility of bladder cancer cells. Int. J. Cancer, 114, 182-189.
8. Nishizawa,K. et al. (2010) Fluorescent imaging of high-grade bladder cancer using a specific antagonist for chemokine receptor CXCR4. Int. J. Cancer, 127, 1180-1187.
9. Nishiyama,A. et al. (1999) Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. J. Biol. Chem., 274, 21645-21650.
10. Watanabe,R. et al. (2010) Anti-oxidative, anti-cancer and anti-inflammatory actions by thioredoxin 1 and thioredoxin-binding protein-2. Pharmacol. Ther., 127, 261-270.
11. Zhou,R. et al. (2010) Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat. Immunol., 11, 136-140.
12. Yang,X. et al. (1998) Expression of a vitamin D-regulated gene (VDUP-1) in untreated- and MNU-treated rat mammary tissue. Breast Cancer Res. Treat., 48, 33-44.
13. Ikarashi,M. et al. (2002) Vitamin D3 up-regulated protein 1 (VDUP1) expression in gastrointestinal cancer and its relation to stage of disease. Anticancer Res., 22, 4045-4048.
14. Takahashi,Y. et al. (2002) Up-regulation of vitamin D3 up-regulated protein 1 gene in response to 5-fluorouracil in colon carcinoma SW620. Oncol. Rep., 9, 75-79.
15. Escrich,E. et al. (2004) Identification of novel differentially expressed genes by the effect of a high-fat n-6 diet in experimental breast cancer. Mol. Carcinog., 40, 73-78.
16. Ito,M. et al. (2007) P21-activated kinase 1: a new molecular marker for intravesical recurrence after transurethral resection of bladder cancer. J. Urol., 178, 1073-1079.
17. Holyoake,A. et al. (2008) Development of a multiplex RNA urine test for the detection and stratification of transitional cell carcinoma of the bladder. Clin. Cancer Res., 14, 742-749.
18. Nishinaka,Y. et al. (2004) Loss of thioredoxin-binding protein-2/vitamin D3 up-regulated protein 1 in human T-cell leukemia virus type I-dependent T-cell transformation. Cancer Res., 64, 1287-1292.
19. Oka,S. et al. (2006) Impaired fatty acid utilization in thioredoxin binding protein-2 (TBP-2)-deficient mice: a unique animal model of Reye syndrome. FASEB J., 20, 121-123.
20. Tamamura,H. et al. (2003) T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett., 550, 79-83.
21. Dutta,K.K. et al. (2005) Two distinct mechanisms for loss of thioredoxin-binding protein-2 in oxidative stress-induced renal carcinogenesis. Lab. Invest., 85, 798-807.
22. Sheth,S.S. et al. (2006) Hepatocellular carcinoma in Txnip-deficient mice. Oncogene, 25, 3528-3536.
23. Kwon,H.J. et al. (2010) Vitamin D3 upregulated protein 1 suppresses TNFα-induced NF-κB activation in hepatocarcinogenesis. J. Immunol., 185, 3980-3989.
24. Jeon,J.H. et al. (2005) Tumor suppressor VDUP1 increases p27(kip1) stability by inhibiting JAB1. Cancer Res., 65, 4485-4489.
25. Castillo-Martin,M. et al. (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol. Oncol., 28, 401-408.
26. Zaravinos,A. et al. (2011) Implication of RAF and RKIP genes in urinary bladder cancer. Pathol. Oncol. Res., 17, 181-19.
27. Metalli,D. et al. (2010) The insulin-like growth factor receptor I promotes motility and invasion of bladder cancer cells through Akt- and mitogen-activated protein kinase-dependent activation of paxillin. Am. J. Pathol., 176, 2997-3006.
28. Kumar,B. et al. (2009) Differential effects of MAPKs signaling on the growth of invasive bladder cancer cells. Int. J. Oncol., 34, 1557-1564.
29. Monami,G. et al. (2006) Proepithelin promotes migration and invasion of 5637 bladder cancer cells through the activation of ERK1/2 and the formation of a paxillin/FAK/ERK complex. Cancer Res., 66, 7103-7110.
30. Youssef,R.F. et al. (2009) Molecular targets and targeted therapies in bladder cancer management. World J. Urol., 27, 9-20.